clinical trial · NCT07282054
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes
Tonghua Dongbao Pharmaceutical Co.,Ltd·phase3·completed·n = 550
Type 1 DiabetesTHDB0206Insulin LisproInsulin Glargine
brief summary
This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin glargine injection U-100 in Chinese participants with T1DM.
started
Apr 13, 2022
primary completion
Jan 23, 2025
completion
Jan 24, 2025
last updated
Dec 15, 2025
official title
A Phase 3, Randomized, Open-Label, Multicenter, Active-controlled Trial Comparing Efficacy and Safety of THDB0206 Injection With Insulin Lispro Injection Combined With Insulin Glargine Injection U-100 in Chinese Participants With Type 1 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol